Malignant neoplasms of mesothelial and soft tissue
2022 ICD-10-CM Diagnosis Code C46
2022 ICD-10-CM Diagnosis Code C46
2016 2017 2018 2019 2020 2021 2022 Non-Billable/Non-Specific Code
- C46 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
- The 2022 edition of ICD-10-CM C46 became effective on October 1, 2021.
- This is the American ICD-10-CM version of C46 - other international versions of ICD-10 C46 may differ.
Code First Help
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition.
The following code(s) above C46
contain annotation back-references
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to C46
- A cancer that causes patches of abnormal tissue to grow under the skin,
- A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (aids).
- A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in jewish and italian males in europe and the United States. An aggressive variant in young children is endemic in some areas of africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in aids patients. (from Dorland, 27th ed & holland et al., cancer medicine, 3d ed, pp2105-7) hhv-8 is the suspected cause.
- A type of cancer characterized by the abnormal growth of blood vessels that develop into skin lesions or occur internally.
- Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. The patches are usually red or purple and are made of cancer cells and blood cells. The red and purple patches often cause no symptoms, though they may be painful. If the cancer spreads to the digestive tract or lungs, bleeding can result. Lung tumors can make breathing hard.before the hiv/aids epidemic, ks usually developed slowly. In hiv/aids patients, though, the disease moves quickly. Treatment depends on where the lesions are and how bad they are. Treatment for hiv itself can shrink the lesions. However, treating ks does not improve survival from hiv/aids itself. nih: national cancer institute
- Multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas; occurs spontaneously in jewish and italian males; aggressive variant in young children is endemic in some areas of africa; a third form occurs in about 0.04% of kidney transplant patients; there is also a high incidence in aids patients; human herpesvirus 8 is the suspected cause.
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
Code annotations containing back-references to C46:
ICD-10-CM Codes Adjacent To C46
Unspecified malignant neoplasm of skin, unspecified
Basal cell carcinoma of skin, unspecified
Squamous cell carcinoma of skin, unspecified
Other specified malignant neoplasm of skin, unspecified
Mesothelioma of pleura
Mesothelioma of peritoneum
Mesothelioma of pericardium
Mesothelioma of other sites
Kaposi's sarcoma of skin
Kaposi's sarcoma of soft tissue
Kaposi's sarcoma of palate
Kaposi's sarcoma of lymph nodes
Kaposi's sarcoma of gastrointestinal sites
Kaposi's sarcoma of lung
Kaposi's sarcoma of unspecified lung
Kaposi's sarcoma of right lung
Kaposi's sarcoma of left lung
Kaposi's sarcoma of other sites
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.